Pharma BD Deal Intelligence
Gilead acquires CymaBay Therapeutics for $4.3 billion, gaining seladelpar for primary biliary cholangitis and significantly expanding its liver disease…
Liver Disease portfolio sales rose 6% to $3.2B in FY2025 and 17% to $844M in Q4 2025 vs prior-year periods, primarily driven by higher demand for Livdelzi…
Phase 3 IDEAL trial met its primary endpoint: Livdelzi (seladelpar) delivered statistically significant composite ALP normalization (ALP <=1.0x ULN and…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Gilead acquired CymaBay for $4.4B for seladelpar for primary biliary cholangitis.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / CymaBay Therapeutics (this deal) | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Gilead Sciences Inc. / Nurix Therapeutics Inc. | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Immunomedics Inc. | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
| Gilead Sciences Inc. / Myogen Inc. | 2006 | $2.5B | 62 |
← Browse all deals · How we score deals
More: 2024 deals · Gilead Sciences Inc. deals · Gastroenterology deals